Early Antibiotic Therapy and Vaccination

Vaccination Reaction Clinical Trial

Official title: Impact of Early Antibiotic Therapy on Vaccination Response in Preterm Infants

Status Recruiting

Clinical Trial Summary

Neonatal Sepsis is one of the most common causes of death in preterm infants. Therefore, up to 80% of very low birth weight infants receive antibiotic therapy in their first week of life. Antibiotic therapy is one of the most important influencing factors for the establishment of the intestinal microbiome, which in turn modulates neonatal immune development. In this pilot study, it will be investigated, if antibiotic therapy in the first week of life influences the vaccination response of preterm infants.

Clinical Trial Description

The aim of the study is to compare antibody titers against Hepatitis B, Polio, Pertussis, Haemophilus influenza B, Tetanus, Diphteria and Pneumococcus in very low birth weight infants (VLBWI) infants who received antibiotic therapy in their first week of life and who did not. In this pilot study, 20 VLBWI infants will be included (10 per group). Infants will be matched fo age and gender. ;

Related Conditions & MeSH terms

• Vaccination Reaction

• NCT number: NCT04109833
• Study type: Observational
• Source: University Hospital Tuebingen
• Contact: Natascha Köstlin-Gille, Dr. med.
• Phone: 0049-7071-2984743
• Email: natascha.koestlin@med.uni-tuebingen.de
• Status: Recruiting
• Start date: September 27, 2019
• Completion date: October 2021